[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "140 million infections in US", "description": "Or is it many more that that? If you would like John\u2019s text books, (it is free to download the PDFs)\n\nLink to free download of my 2 textbooks\n\nhttp://159.69.48.3/\n\nPhysiology book in hard copy\nhttps://www.ebay.co.uk/itm/154770452796?mkevt=1&mkcid=16&mkrid=710-127635-2958-0\n\n\n\n140 million Americans have had coronavirus\n\nNationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories)\n\nhttps://covid.cdc.gov/covid-data-tracker/#national-lab\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html\n\n58 % up to 17 years, have antibodies infection\n\nLast data, 72,000 blood samples taken in January\n\nPercentage, United States, resolving or past infection with SARS-CoV-2,\n\nbut not how much antibody is present,\n\ndo not necessarily indicate the percentage of people with sufficient antibody to protect against reinfection\n\nThese percentages do not include people who have been vaccinated against SARS-CoV-2 and have no history of infection. \n\nResults directly from paper\n\nhttps://pubmed.ncbi.nlm.nih.gov/33231628/\n\nEstimated SARS-CoV-2 Seroprevalence in the US as of September 2020\n\n\n\n \n\n\n \n\n\n\n \n\n\n\n\nNationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations)\n\nhttps://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence\n\nPercentage, 16 years and older, developed antibodies against SARS-CoV-2 from vaccination or infection.\n\nDecember 2021\n\n\n \n\n\nAustralia\n\nhttps://www.health.gov.au/health-alerts/covid-19/case-numbers-and-statistics\n\n \n\n\n\n\n\nUK, ONS\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nWeek ending 19 February\n\n3.84% in England (1 in 25 people) \n\n3.23% in Wales (1 in 30 people)\n\n7.23% in Northern Ireland (1 in 14 people)\n\n4.57% in Scotland (1 in 20 people)", "link": "https://www.youtube.com/watch?v=BaUK31EjRRo", "date_published": "2022-03-04 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Brief global pandemic update", "description": "Most areas getting over omicron pandemic wave, a few still in the early stages\nhttps://ourworldindata.org/coronavirus", "link": "https://www.youtube.com/watch?v=TbOoGgtnXUg", "date_published": "2022-03-04 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vitamin D, Strong evidence from Israel", "description": "that low levels of vitamin D patients do much worse than high levels of vitamin D patients.\n\nVitamin D deficiency prevalence and cardiovascular risk in Israel\n\nhttps://pubmed.ncbi.nlm.nih.gov/20955219/\n\nN = 34,874\n\nVit D levels, women, 22.7 ng mL\n\nVit D levels, men, 23.2 ng mL\n\nPrevalence of vitamin D deficiency or insufficiency \n\n(vitamin D levels less than 30 ng mL)\n\nWomen, 77\u00b75%,\n\nMen, 79\u00b72%\n\nOnly little variation when stratified by age\n\nPrevalence of deficiency in Israel, similar to less sunny regions\n\nTwo groups\n\nGroup with vitamin D less than 15 ng mL\n\nGroup with vitamin D levels more than 30 ng mL\n\nless than 0\u00b7031 age-adjusted odds ratios for the presence of,\n\nHypertension\n\nDiabetes mellitus\n\nDyslipidemia\n\nObesity\n\nPeripheral vascular disease\n\nPre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness\n\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263069\n\nhttps://www.webmd.com/lung/news/20220208/vitamin-d-deficiency-tied-to-severe-covid\n\nPotential correlation, low vitamin D and increased risk of infection with SARS-CoV-2,\n\nand poorer clinical outcomes\n\nThis study examines\n\nAny relationship exists between,\n\npre-infection serum 25-hydroxyvitamin D (25(OH)D) level,\n\nWith disease severity and mortality due to SARS-CoV-2.\n\nApril 7th, 2020 and February 4th, 2021\n\nPositive polymerase chain reaction tests for SARS-CoV-2,\n\nsearched for historical 25(OH)D levels measured 14 to 730 days prior\n\nDesign\n\nPatients admitted were categorized,\n\ndisease severity and level of 25(OH)D\n\nDeficient, less than 20 ng/mL (n = 133)\n\nInsufficient, 20 to 30 ng/mL (n = 36)\n\nAdequate, 30 to less than 40 ng/mL (n = 30)\n\nHigh-normal, 40 ng/mL or greater (n = 40)\n\nAccounted for changes throughout the year\n\nResults\n\n1,176 patients admitted\n\n253 had records of a 25(OH)D level prior to infection\n\nA lower vitamin D status was more common in patients with the severe or critical disease\n\nIn patients with severe or critical disease\n\n87.4% had less than 20 ng/mL\n\nIn patients with mild or moderate disease\n\n34.3% had Less than 20 ng/mL\n\nP less than 0.001\n\nPatients with vitamin D deficiency (less than 20 ng/mL) \n\n14 times more likely to have severe or critical disease,\n\nOdds ratio 14 (95% confidence interval 4 to 51) p less than 0.001\n\nMortality, patients with sufficient vitamin D levels\n\n2.3%\n\nMortality, patients with deficient vitamin D levels\n\n25.6% mortality rate (p less than 0.001)\n\nConclusions\n\nAmong hospitalized COVID-19 patients, pre-infection deficiency of vitamin D was associated with increased disease severity and mortality.\n\nLow vitamin D status has been associated with a range of autoimmune, cardiovascular, and infectious diseases\n\nEssential immunologic mediator\n\nInhibitory effects on pro-inflammatory cytokines, \n\nTNF-alpha and IL-6\n\nEpidemiological risk factors for vitamin D deficiency\n\nDarker skin pigmentation\n\nLow sun exposure\n\nSkin-covering clothes\n\nSun creams\n\nDiet low in fish and dairy products\n\nAn association between low 25-hydroxyvitamin D (25(OH)D) levels and an increased risk of acquiring influenza and respiratory viruses\n\nMeta-analyses of randomized controlled trials, 2007 and 2020\n\nVitamin D supplementation reduced the risk of acute respiratory infection as compared with placebos\n\nFactors associated with poorer COVID-19 prognoses\n\nGeographic location in northern countries\n\nOlder age\n\nBlack and minority ethnic groups\n\nObesity\n\nPreexisting conditions, diabetes and hypertension\n\nthese risk factors are also independently associated with vitamin D deficiency\n\nDifficult to ascertain a definitive causative effect of baseline vitamin D status on a clinical presentation during active COVID-19 infection\n\nA cosinor model, to account for the cycles of serum vitamin D values across the seasons\n\nVitamin D levels below less than 20 ng/mL\n\nIsraeli Arabs 64.3%\n\nIsraeli non-Arabs 35.7%", "link": "https://www.youtube.com/watch?v=unaG99XbsKk", "date_published": "2022-03-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]